Elsaad products
Member Login


New Products
Newsletter
 
 
Our Products
 
Product Name
:
OLMESONE
Chemical Name
:
MOMETASONE FUROATE
Therapeutic Category
:
Anti-inflammatory drugs
Pharmacologic Category
:
Corticosteroid, Topical
Pharmaceutical Form
:
Cream
Composition
:
MOMETASONE FUROATE 1 MG
Monitoring Parameters
Dosing
 
Dosing: Adult
Treatment of corticosteroid-responsive dermatoses: Topical: Apply sparingly, do not use occlusive dressings. Therapy should be discontinued when control is achieved; if no improvement is seen in 2 weeks, reassessment of diagnosis may be necessary.
Cream: Apply a thin film to affected area once daily

Dosing: Pediatric

Treatment of corticosteroid-responsive dermatoses: Topical:
Cream: Children ≥2 years: Refer to adult dosing. Do not use in pediatric patients for longer than 3 weeks.

Dosing: Geriatric

Refer to adult dosing.
Use
 
Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid)
Adverse Reactions
 
1% to 10%: Dermatologic: Bacterial skin infection, burning, furunculosis, pruritus, skin atrophy, tingling/stinging
<1% (Limited to important or life-threatening): Folliculitis, glucocorticoid levels decreased (pediatric patients), moniliasis, paresthesia, rosacea, skin depigmentation, skin atrophy
Cataract formation, reduction in growth velocity, and HPA axis suppression have been reported with other corticosteroids
Contraindications
 
Hypersensitivity to mometasone or any component of the formulation
Warnings / Precautions Drug
 
Concerns related to adverse effects:
• Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.
• Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.
• Sensitization: Topical use of corticosteroids has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.
• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.
Special populations:
• Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.
• Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.
Dosage form specific issues:
• Appropriate use: Avoid use of topical preparations with occlusive dressings or on weeping or exudative lesions.
Metabolism/Transport Effects
Substrate of CYP3A4 (minor)
Interactions
 
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Risk X: Avoid combination
Conivaptan: May increase the serum concentration of CYP3A4 Substrates (Low risk). Risk C: Monitor therapy
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy
Telaprevir: May increase the serum concentration of Corticosteroids. Corticosteroids may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives. If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects. Risk D: Consider therapy modification
Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates. Risk C: Monitor therapy
Pregnancy
 
C
Pregnancy Implications
Adverse events were observed in animal studies following topical and SubQ administration. Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy. Monitor these infants closely after birth. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.
Lactation
 
Excretion in breast milk unknown/use caution
Breast-Feeding Considerations
Systemic corticosteroids are excreted in human milk; however, information for mometasone is not available. Hypertension in the nursing infant has been reported following corticosteroid ointment applied to the nipples. Use with caution.
Mechanism of Action
 
May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Leukocytes and macrophages may have to be present for the initiation of responses mediated by the above substances. Inhibits the margination and subsequent cell migration to the area of injury, and also reverses the dilatation and increased vessel permeability in the area resulting in decreased access of cells to the sites of injury.
Pharmacodynamics / Kinetics
 
Absorption: Ointment: 0.7%; increased by occlusive dressings
 
   
 
Powered by: TSS-EST.COM